Search the Newsreel

A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12

This article provides a quick overview of analyst ratings for Sight Sciences (SGHT.US), indicating a forecast share price between $8 and $12. It likely includes details on recent analyst actions and potential price targets for the company.

Spruce (SPRB) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Reaction Snapshot: Shares Finish 0.14% Lower in the Current Update - Non-GAAP Earnings

Pacific Biosciences CEO Mark van Oene sells $30,409 in stock

Pacific Biosciences CEO Mark van Oene sold 26,911 shares of company stock for $30,409 on August 17, 2026. This transaction was primarily to cover tax withholding obligations associated with the vesting of restricted stock units. The sale occurred as PACB stock trades near its …

Gilead Sciences CFO Andrew Dickinson sells $415k in shares

Gilead Sciences CFO Andrew Dickinson sold 3,000 shares of company stock for $138.36 per share, totaling $415,080, on August 17, 2026. This transaction was part of a pre-arranged Rule 10b5-1 trading plan. Despite the sale, Dickinson still beneficially owns 165,646 shares, and the stock …

Mayukh Sukhatme Sells 284,707 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Mayukh Sukhatme, an insider at Roivant Sciences (NASDAQ:ROIV), sold 284,707 shares of the company's stock for approximately $10.3 million on August 17th, 2026, reducing his position by 1.51%. This follows two other recent sales by Sukhatme. Despite these insider sales, analysts maintain a "Moderate …

Roivant (ROIV) CIO sells shares after exercising $3.85 options

Roivant Sciences Ltd.'s President & CIO, Mayukh Sukhatme, exercised stock options for 664,826 common shares at $3.85 per share across August 14, 17, and 18, 2026. These shares were then sold in open-market transactions with weighted average prices ranging from $36.23 to $37.18. The …

Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares

Roivant Sciences insider Mayukh Sukhatme sold 243,177 shares for approximately $8.81 million, retaining 18.63 million shares. This sale is part of three recent transactions totaling around $24.16 million. Despite a quarterly loss, Roivant Sciences beat analyst estimates and its shares rose 3.1% to near …

Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 136,942 Shares

Mayukh Sukhatme, an insider at Roivant Sciences (NASDAQ:ROIV), sold 136,942 shares of the company's stock for approximately $5.03 million. Despite this recent sale, Sukhatme still directly owns 18.63 million shares and had prior sales totaling over $19.1 million in August. Roivant Sciences' stock saw …

Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock

Pacific Biosciences of California (NASDAQ:PACB) insider Oene Mark Van sold 26,911 shares of the company's stock for approximately $30,409. The sale was primarily to cover tax withholding obligations related to vested equity awards, reducing his holdings by 0.98%. This transaction occurred as PACB shares …

Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences CFO Andrew Dickinson sold 3,000 shares of the company's stock for $415,080 under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by 1.78%. This sale comes as Gilead's stock rose 3.3% to $143.44, following better-than-expected quarterly results and a declared dividend …

Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data

Neurocrine Biosciences (NBIX) is potentially 28% undervalued according to a recent analysis, following positive KINECT-PRO Phase 4 results for its drug INGREZZA. Despite a recent share price dip, NBIX has shown strong long-term returns and has a diverse CNS pipeline, suggesting significant future growth …

Gilead Sciences chief comm & corp aff officer sells $3.85m stock

Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), sold 28,000 shares of company stock for approximately $3.85 million on August 17, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred alongside the exercise of non-qualified stock …

Gilead Sciences: CFO Andrew Dickinson verkauft Aktien im Wert von 415.000 $

El director financiero de Gilead Sciences vende acciones por 415.000 dólares

Twist (TWST) EPS and Revenue Review: The Bottom-Line Figure Trails Its Comparison in the Current Update; Session Reaction: The Stock Ends Down 6.68% in the Available Record - Post-Earnings Drift

How Investors May Respond To Thermo Fisher Scientific (TMO) Expanding Access To Parkinson’s Proteomic Data

Thermo Fisher Scientific (TMO) has completed large-scale Olink Explore HT proteomic analysis on Parkinson's samples from The Michael J. Fox Foundation, making the data accessible for research. This initiative reinforces Thermo Fisher's role in precision medicine and its focus on innovation and recurring revenue. …

Skye Bioscience (SKYE) holder sells shares, funds Redx merger

5AM-affiliated funds and individuals have updated their beneficial ownership in Skye Bioscience (SKYE) and detailed a strategic merger with Redx Pharma Limited. Skye will acquire Redx shares through a UK Scheme of Arrangement, with Redx pre-transaction equity holders expected to own 46.17% of the …

Why Ciena Stock Tanked by Almost 9% on Tuesday

Ciena's stock dropped by almost 9% after TD Cowen analyst Joshua Buchalter lowered his fair value assessment for the company from $675 to $575 per share. Despite this reduction, Buchalter maintained a "buy" recommendation, citing recent price weakness and overall bullish prospects for semiconductor …

PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding

PacBio (NASDAQ: PACB) CEO Mark Van Oene sold 26,911 shares of common stock on August 17, 2026, at a weighted average price between $1.13 and $1.15 per share. This sale was automatically conducted to cover tax withholding obligations associated with the vesting of restricted …

Microba Life Sciences Insiders Forfeit On 21% Gains After Selling Stock

Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Stock

Gilead Sciences insider Johanna Mercier sold 28,000 shares of GILD stock for $3.85 million at an average price of $137.64, reducing her holdings by 19.15%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, Gilead's stock traded up …

Marc Graff Sells 4,995 Shares of Ciena (NYSE:CIEN) Stock

Ciena CFO Marc Graff sold 4,995 shares of CIEN stock on August 14th for over $2.15 million, reducing his position by 4.44%. The stock experienced a 9.0% decline on Tuesday, trading at $405.03. Despite the sale and stock drop, Ciena reported strong quarterly earnings, …

Ciena SVP & CFO Marc Graff sells $2.15m in company stock

Marc D. Graff, Senior Vice President and Chief Financial Officer at CIENA CORP, sold 4,995 shares of the company's common stock for over $2.15 million on August 14, 2026, as part of a Rule 10b5-1 trading plan. This sale occurred after CIENA's stock surged …

Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock

Pacira BioSciences insider Jonathan Slonin sold 3,040 shares of the company's stock for a total of $70,619.20. This transaction reduced his ownership by 1.39% to 216,384 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock traded up 3.3% to …

Gilead (NASDAQ: GILD) CFO sells shares under 10b5-1 plan

Gilead Sciences, Inc. (NASDAQ: GILD) Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on August 17, 2026, at a price of $138.36 per share. This transaction was carried out under a pre-adopted Rule 10b5-1 trading plan. After the sale, Mr. …

USANA (USNA) Quarterly Update: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Price Action: The Market Price Moves 2.72% Higher in the Current Update - Post-Earnings Drift

H.C. Wainwright raises Alto Neuroscience price target to $55

H.C. Wainwright has increased its price target for Alto Neuroscience (NYSE:ANRO) to $55 from $50, maintaining a Buy rating. This adjustment follows Alto's announcement of its Q2 2026 results and the naming of its ALTO-207 development plan as the PACE program, which includes three …

Gilead Sciences Inc (GILD) Stock Up 3.2% but GF Value Says Overvalued

Gilead Sciences Inc (GILD) shares increased by 3.2% to $143.44, but GuruFocus's GF Value indicates the stock is 34.9% overvalued, with an estimated intrinsic value of $106.32. The company's GF Score is 74/100, highlighting strong profitability but weak momentum and insider selling of $77.5 …

USANA (USNA) Q2 2026 Earnings Call Transcript

Ciena (NYSE: CIEN) exec sells 2,500 shares under trading plan

David M. Rothenstein, SVP and Chief Strategy Officer of Ciena (NYSE: CIEN), sold 2,500 shares of common stock on August 14, 2026, at $438.10 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on October 10, 2025. Following the sale, …

Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan

Pacira BioSciences (PCRX) Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026, at $23.23 per share through an open-market transaction. This sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Following the transaction, …

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Sabrina Martucci Johnson, CEO of Daré Bioscience, has been recognized on Forbes' 2026 “50 Over 50: Innovation” list for her significant impact in women's health. The company, founded in 2015, is evolving from a clinical-stage biotechnology firm to a multi-product women's health company with …

SELLAS (SLS) Earnings Recap: EPS Misses Its Estimate in the Reported Period; Trading Response: Shares Move Higher 0.77% for the Current Session - Return On Assets

Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates

BioHarvest (BHST) Earnings Recap: The Available Earnings Metric Delivers a Miss in the Reported Period; The Stock Loses 1.15% in the Available Record - Earnings Manipulation Risk

Ciena (NYSE: CIEN) exec sale leaves 38,407-share stake

Ciena's Senior Vice President, Gage Brodie, sold 1,200 shares of common stock at $439.24 per share on August 17, 2026, as per a Rule 10b5-1 trading plan. Following this transaction, Brodie retains a beneficial ownership of 38,407 shares, which includes unvested Restricted Stock Units …